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Abstract
K-Ras-induced lung cancer is a very common disease, for which there are currently no effective
therapies. Because therapy directly targeting the activity of oncogenic Ras has been unsuccessful, a
different approach for novel therapy design is to identify critical Ras downstream oncogenic targets.
Given that oncogenic Ras proteins activate the transcription factor NF-κB, and the importance of
NF-κB in oncogenesis, we hypothesized that NF-κB would be an important K-Ras target in lung
cancer. To address this hypothesis, we generated an NF-κB-EGFP reporter mouse model of K-Ras-
induced lung cancer and determined that K-Ras activates NF-κB in lung tumors in situ. Furthermore,
a mouse model was generated where activation of oncogenic K-Ras in lung cells was coupled with
inactivation of the NF-κB subunit p65/RelA. In this model, deletion of p65/RelA reduces the number
of K-Ras-induced lung tumors both in the presence and absence of the tumor suppressor p53. Lung
tumors with loss of p65/RelA have higher numbers of apoptotic cells, reduced spread and lower
grade. Using lung cell lines expressing oncogenic K-Ras, we show that NF-κB is activated in these
cells in a K-Ras-dependent manner and that NF-κB activation by K-Ras requires IKKβ kinase
activity. Taken together, these results demonstrate the importance of the NF-κB subunit p65/RelA
in K-Ras induced lung transformation and identify IKKβ as a potential therapeutic target for K-Ras-
induced lung cancer.
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INTRODUCTION
Lung cancer is the second most common type of cancer in the U.S., yet it is the leading cause
of cancer deaths (1). Importantly, activating point mutations in the K-Ras GTPase gene occur
in a large number of lung cancer patients (2–4). These mutations are not only associated with
poor prognosis and therapy resistance (5,6), but have also been causally linked to the oncogenic
process. In this regard, expression of mutant K-Ras in mice is sufficient to cause transformation
and tumor formation (7,8). Effective abrogation of K-Ras activity reverts malignant cells to a
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non-malignant phenotype (9–12). Therefore, cancer therapy targeting K-Ras would be
expected to produce a clinical benefit. Unfortunately, therapies aimed at inhibiting the
biological activity of K-Ras have so far been unsuccessful (13). In order for more effective
therapies for K-Ras-induced lung cancer to be generated, the critical K-Ras effectors involved
in oncogenesis need to be identified.
The transcription factor NF-κB is a dimeric complex formed by members of a conserved family
of proteins that share a motif designated as the Rel Homology Domain. NF-κB is expressed
ubiquitously, and the primary NF-κB member responsible for transcriptional activation of
target genes is the subunit p65/RelA (14,15). In unstimulated non-transformed cells, most NF-
κB complexes are held in an inactive cytoplasmic form through interactions with the inhibitor
of κB (IκB) proteins. Upon stimulation with cytokines or other relevant molecules, IκB is
phosphorylated by the IκB kinase (IKK) complex and undergoes rapid ubiquitination and
proteasome-mediated degradation. The NF-κB subunits are then released and accumulate in
the nucleus to regulate target gene transcription (14,15).
Even though NF-κB has been reported to have a tumor suppressive role in certain specific
settings (16), the majority of studies show that, when activated, NF-κB can contribute to
oncogenic transformation (17). Indeed, NF-κB is important for cellular transformation induced
by oncoproteins (18,19). Not surprisingly, constitutive NF-κB activation has been detected in
a variety of human malignancies (17), including lung cancer (20).
Importantly, NF-κB is activated by oncogenic Ras. Studies from our group revealed that
oncogenic H-Ras induces cellular transformation in fibroblasts by activating NF-κB (18); and
NF-κB activation is required to suppress oncogenic H-Ras-induced apoptosis (21). Other
studies have demonstrated a correlation between increased NF-κB activity and expression of
oncogenic K-Ras (20,22). Duran et al (23) demonstrated a mechanistic link between K-Ras,
IKK, and NF-κB through the signaling adaptor p62. Based on these cell-based studies, it is
important to determine if NF-κB is required for development of K-Ras-induced tumors in
situ.
Here we demonstrate that oncogenic K-Ras activates NF-κB in lung epithelial cells in situ. In
addition, genetic deletion of the NF-κB subunit p65/RelA in a K-Ras induced lung cancer
mouse model reduces lung tumorigenesis both in the presence and absence of the tumor
suppressor p53. K-Ras-dependent NF-κB activity was observed in transformed human lung
epithelial cells. Interestingly, NF-κB activity in both murine and human K-Ras-transformed
cells requires IKKβ kinase activity. These results demonstrate NF-κB (p65/RelA) as an
important K-Ras oncogenic effector in lung cancer and suggest pharmacological inhibition of
IKKβ activity as a therapeutic approach for K-Ras-related malignancies.
METHODS
Animal husbandry and Cre-expressing adenovirus (adenocre) administration
Lox-stop-lox (LSL) K-RasG12D mice (24), cis-κB-EGFP mice (25), p65/RelA conditional mice
(26), p53 conditional mice (27) and mice generated by inter-strain crossings were housed in
pathogen-free conditions according to the protocols approved by the UNC Institutional Animal
Care and Use Committee. Lung tumor induction was performed by intranasal administration
of 1×107 plaque forming units (pfus) of adenocre (Gene Transfer Vector Core, University of
Iowa, Iowa City, IA) in selected animals at 8 weeks of age, as described (24).
Histopathological analysis
Mice were euthanized by intraperitoneal administration of 250mg/kg avertin followed by
surgical resection of the portal vein. Lungs were perfused with saline and inflation-fixed
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overnight with formalin 10%. Fixed tissues were be embedded in paraffin, sectioned at 5
micrometer thickness and stained with hematoxylin/eosin.
Live imaging and laser scanning microscopy
The whole-body small animal fluorescence imaging system (Xenogen IVIS 100 system,
Caliper Life Sciences, Hopkinton, MA) equipped with a charge-coupled device camera was
used to visualize GFP fluorescence emission using GFP filter for excitation (445–490 nm) and
emission (515–575 nm). Analysis of the images was performed using Living Image software
(Caliper Life Sciences, Hopkinton, MA). Laser scanning microscopy was performed using a
Nipkow-type spinning disk confocal scan head (CSU-10, Yokogawa Corporation, Newnan,
GA) with a 10X objective, attached to an inverted microscope (model IX-81, Olympus, Center
Valley, PA). Images were acquired using a CCD camera (model C4742-80-12AG, Hamamatsu,
Bridgewater, NJ).
Western Blotting and Immunohistochemistry
Western Blotting and Immunohistochemistry were performed as described (26,28). The
antibodies used and respective catalog numbers were as follows: anti-phospho-IκBα-Ser32/36
(9246), anti-IκBα (9242), anti-phosphoAKT-Ser473 (4058), anti-phospho-p44/42-MAPK-
Thr202/Tyr204 (4370), anti-p44/42-MAPK (4696), anti-phospho-IKKα/β-Ser176/180 (2697)
and anti-p65/RelA (4764) antibodies were from Cell Signaling (Danvers, MA); anti-pan-
Ras12D (PC10L) and anti-c-K-Ras (OP24) were from Calbiochem (San Diego, CA); we also
used anti-GFP (JL-8, Clontech, Mountain View, CA), anti-β-tubulin (sc-9104, Santa Cruz
Biotechnology, Santa Cruz, CA) and anti-IKKβ (05-535, Chemicon, Temecula, CA)
antibodies.
Detection of Cre-mediated recombination
Cre-mediated recombination of the LSL-K-Ras allele and p65 conditional allele was detected
by PCR amplification with primers flanking the deleted site (sequences available upon request).
Amplification of the wildtype allele results a 3.9 kilobase product and amplification of the
deleted allele results in a 1.3 kilobase product. Amplification was performed by denaturation
at 95°C for 1min followed by 35 cycles of amplification at 98°C for 10 seconds, 52°C for 30
seconds and 72°C for 90 seconds with a final extension step of 10min at 72°C.
Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL)
assay
Tissue sections were deparaffinized, rehydrated, and stained according to the ApopTag Plus
in situ apoptosis detection kit(Millipore, Billerica, MA) instructions.
Tumor number and grade analysis
Tumor slides from each lung lobe (same orientation and level section used for each lobe) were
scored for number, spread and grade blindly. For analysis of tumor spread, tumors were divided
either into bronchial lesions or alveolar lesions according to the following criteria. Bronchial
lesions were tumor masses either completely contained within the bronchial compartment or
lesions where the spread into the alveolar compartment was smaller than the bronchial
component. Alveolar lesions were lesions restricted to the alveolar compartment (excluding
adenomatous alveolar hyperplasia), or lesions were the alveolar spread was larger than the
bronchial component (including solid tumors). For analysis of tumor grade, each tumor was
given a score of 1 to 5 based on previously described criteria (29).
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Generation of KE67 cell line
Lung tumors from K-Ras/NF-κB mice were dissected under asseptic conditions and cut into
small pieces (around 2mm in diameter). Each piece was placed in a 100mm cell culture dish
with 2ml of 0.25% trypsin-EDTA (Invitrogen) and minced with a sterile razor blade. After
trypsinization, 8ml of complete medium were added to the dish and cells were transferred to
15ml conical tubes. Untrypzinized tumor chunks and tissue debris were allowed to sediment
for 10 min. Both the supernatant and sedimented fractions were collected and plated separately
in 100mm dishes. Cells were then kept on culture and passed when confluency was reached.
To inhibit fibroblast growth, the culture medium was supplemented with Mouse FibrOut™ 9
(Chi Scientific, Maynard, MA) for a week.
Cell culture
Cell passages were kept to a minimum and no cells were passaged continuously for more than
six months. Low passage SALEB and SAKRAS cells were obtained from Dr. Scott Randell
and cultured in serum-free bronchial epithelium growth medium (BEGM, Clonetics-Lonza,
Allendale, NJ). These cells were originally selected in medium containing a triple antibiotic
cocktail and subsequently characterized by real-time PCR for expression of the genes used for
immortalization and transformation (30). Short Tandem Repeat-DNA profile authenticated
NCI-H358 cells were obtained from ATCC (Manassas, VA) and maintained in RPMI 1640
(Invitrogen, Carlsbad, CA) supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO).
KE67 cells were generated in the laboratory (as described above) and their origin was
authenticated both by PCR of the excised K-Ras allele, as well as expression of EGFP from
the reporter allele. They were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM,
Invitrogen, Carlsbad, CA) supplemented with 10% FBS and 0.5mM 2-mercaptoethanol (both
from Sigma-Aldrich, St. Louis, MO).
Electrophoretic mobility shift assay (EMSA)
Cells were either transfected or treated with appropriate reagents, nuclear extracts were
prepared and EMSA was performed as previously described (28), using 32P-labeled
oligonucleotide probes corresponding to an NF-κB site within the MHC class I promoter
region.
RNA isolation and Real-time PCR analysis
Total RNA was prepared using TRIZOL reagent (Invitrogen) following the manufacturer’s
protocol and real-time PCR analysis was performed as previusly described (28) in an ABI 7000
Sequence Detection System using TaqMan Gene Expression Assay primer-probe sets (all from
Applied Biosystems, Foster City, CA) for IL-8 (Hs99999034_m1), Bcl-xL (Hs00236329_m1)
and MMP-9 (Hs00234579_m1). Relative quantitation was determined by the ΔΔCt method
using Gusb (Hs99999908_m1) as the endogenous control.
Transfections and Reporter Assays
siRNA transfections were performed as previously described (28) with 100nM of either a non-
targeting siRNA control or siRNA smart pools targeting IKKβ or K-Ras (Dharmacon,
Lafayette, CO). Reporter assays were performed as described (28). For genetic studies, cells
were co-transfected with 100ng of either empty pcDNA3 vector (Invitrogen, Carlsbad, CA)
for control or a pcDNA3 vector encoding the kinase mutant form of IKKβ (IKKβ-KM). For
pharmacological studies, cells were treated treated as indicated (see figure legends). Relative
light units were measured on an Lmax Microplate Luminometer (MolecularDevices,
Sunnyvale, CA).
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2 × 105 KE67 cells plated in 6-well plates were treated with either 0.1% DMSO or 5uM
IKKβ inhibitor CmpdA (31) for 16h. Cells were then scraped in PBS supplemented with 2%
FBS (Sigma) and subsequently analyzed for GFP expression on a Beckman-Coulter Cyan ADP
cytometer (Dako, Carpinteria, CA). Results were analyzed with FlowJo software (Tree Star,
Ashland, OR).
Statistics
All values are presented either as mean ± SD or as representative images of at least three
independent experiments. In the case of animal studies, five mice of each different genotype
were analyzed. All comparisons were made using the unpaired Student t test for samples with
unequal variance. Differences were considered statistically signi cant at p ≤ 0.05 (indicated by
asterisks).
RESULTS
Generation of a NF-κB reporter mouse model of K-Ras-induced lung cancer
In order to determine if NF-κB activity is induced in mouse lung tumors triggered by activation
of oncogenic K-Ras, an NF-κB reporter mouse model of K-Ras-induced lung cancer was
developed. To generate this model, we used oncogenic K-Ras inducible Lox-Stop-Lox (LSL)
K-RasG12D mice (24), where expression of oncogenic K-RasG12D is triggered by Cre
recombinase-mediated removal of the LSL element (Fig. 1A). The LSL-K-RasG12D mice were
then bred to cis-NF-κB-EGFP knock-in mice, which express enhanced green fluorescent
protein (EGFP) under the control of NF-κB cis elements (25). Mice positive for the conditional
K-Ras allele and the NF-κB responsive EGFP reporter allele (referred to as K-RasG12D/NF-
κB mice) were infected by intranasal administration of adenocre in order to activate oncogenic
K-RasG12D specifically in lung epithelial cells and induce lung tumor formation.
NF-κB is activated in mouse K-Ras-induced lung cancers
NF-κB activity in K-RasG12D/NF-κB mice was evaluated by measuring the levels of EGFP
expression in the lungs of tumor-bearing animals. First, non-invasive live fluorescence imaging
was used to measure EGFP expression at 19 weeks post-infection, when lung adenocarcinomas
can be detected (24). As can be seen in Fig. 1A, K-RasG12D/NF-κB mice have higher EGFP
fluorescence emission levels in the chest area than K-RasWT/NF-κB mice (mice positive for
the the NF-κB responsive EGFP reporter allele, but lacking the conditional K-Ras allele). Next,
EGFP expression was measured directly in dissected lungs by laser scanning fluorescence
microscopy. Lung tumors from K-RasG12D/NF-κB animals are EGFP positive (Fig. 1B).
Importantly, the lungs of K-RasWT/NF-κB mice have only a few scattered EGFP positive cells
(Fig. 1B). To rule out the possibility that the EGFP-positive cells within the lung tumors might
be comprised of inflammatory cells (which are part of the tumor microenvironment and require
NF-κB activation for their function (32)), we performed GFP immunohistochemistry. As can
be seen in Figure 1C, many epithelial cells within the lung neoplastic lesions stain positive for
EGFP (middle panel), whereas very few cells stain positive in K-RasWT/NF-κB mice (upper
panel). As expected, the lung neoplastic cells from K-RasG12D positive mice lacking the EGFP
reporter allele are negative for EGFP expression (bottom panel).
In addition to evaluating EGFP reporter activity, we measured levels of the phosphorylated
form (phospho-ser32/36) of the IκBα protein, a marker of NF-κB and IKK activation (Fig. 1D).
When compared to adenocre-infected K-RasWT lungs, the lungs of adenocre-infected K-
RasG12D mice display increased levels of IκBα phosphorylation at Ser32/36 coupled with lower
levels of total IκBα protein (consistent with IKK-induced degradation). In addition, consistent
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with K-Ras activation, K-RasG12D mice display increased levels of phospho-AKT and
phospho-p42/44). Finally, expression of the mutant 12D form of Ras was detected exclusively
in K-RasG12D mice. These results support the EGFP analysis, indicating a higher degree of
NF-κB activity in the lungs of K-RasG12D mice. Taken together these results confirm that NF-
κB is activated in K-Ras-induced murine lung tumors in situ.
Deletion of the NF-κB p65/RelA subunit in the mouse lung decreases K-Ras-induced lung
tumorigenesis
Given that K-Ras-induced lung tumorigenesis triggers NF-κB activation, we asked if genetic
deletion of the NF-κB subunit p65/RelA in the LSL-K-Ras mouse model affects K-Ras-induced
oncogenesis. To achieve p65/RelA inactivation we bred the LSL-K-RasG12D mice to p65fl/fl
conditional mice (26) to obtain LSL-K-RasG12D/p65fl/fl mice. Lungs were then infected with
adenocre to activate K-RasG12D and inactivate p65/RelA simultaneously (K-RasG12D/p65Δ
mice).
As evaluated by pathological examination of dissected lungs at 13 weeks post-infection, K-
RasG12D/p65Δ mice display a significantly reduced number of tumors than K-RasG12D/
p65WT mice (Figure 2A). In order to confirm that recombination of the conditional p65/RelA
allele occurred in the lungs of K-RasG12D/p65Δ mice, we measured excision by PCR (see fig.
2B and supplementary methods). In addition, as revealed by immunohistochemical studies, the
neoplastic lung lesions found in K-RasG12D/p65Δ mice lacked p65/RelA expression (Fig. 2C).
Interestingly, loss of p65/RelA affected, not only the number of lesions formed, but also their
spread. As can be seen in fig. 2D, most lesions formed in the presence of p65/RelA at 13 weeks
post-infection have spread significantly into the alveolar compartment, whereas most lesions
lacking p65/RelA at the same timepoint are still mostly contained within the bronchial
epithelium. As these results indicate, although not absolutely required for tumor formation,
p65/RelA greatly potentiates K-Ras-induced transformation in the lung in situ.
In order to gain insight into the role played by p65/RelA in potentiating K-Ras-induced
oncogenesis, we investigated if loss of p65/RelA in this mouse model affects neoplastic cell
survival. Relevant to this point, NF-κB has been shown, in cell-based studies, to be required
to suppress Ras-induced apoptosis (21). Consistent with these previous findings, very few
apoptotic cells were detected in K-RasG12D/p65WT lesions, whereas a high number of apoptotic
cells were seen in lesions of K-RasG12D/p65Δ animals (Fig 3).
The ability of the NF-κB p65/RelA subunit to potentiate K-Ras-induced lung tumorigenesis
does not depend on the status of the p53 tumor suppressor
The tumor suppressor p53 is a well-known activator of the apoptotic response triggered upon
oncogene activation; it is also known that p53 activity can be negatively regulated by NF-κB
and vice versa (33). Therefore, it would be reasonable to assume that NF-κB can potentiate K-
Ras-induced oncogenesis by suppressing p53 activity. However, contrary to this assumption,
we showed (21) that NF-κB regulates H-Ras-induced transformation in a p53-independent
manner.
In order to address if p65/RelA potentiates K-Ras-induced oncogenesis by suppressing p53
activity, we generated a mouse model of K-Ras-induced lung cancer with combined loss of
p65/RelA and p53 to ascertain whether loss of p53 would block the ability of p65/RelA to
potentiate K-Ras transformation. For this purpose, we bred LSL- K-RasG12D/p65WT/WT and
LSL-K-RasG12D/p65fl/fl models to p53fl/fl mice (27) to generate K-RasG12D/p53Δ/p65WT and
K-RasG12D/p53Δ/p65Δ mice.
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p53 is a strong tumor suppressor on its own, and its loss accelerates K-Ras tumor kinetics
(29). We also observed this accelerated kinetics in animals with combined loss of p65 and p53.
Even though loss of p53 did not seem to affect the number of lesions formed, p53 null tumors
grew faster and progressed to a higher histological grade (not shown). Nonetheless, similar to
what was observed in K-RasG12D mice, loss of p65/RelA in K-RasG12D/p53Δ mice resulted in
a lower frequency of lung tumors (Figure 4A). These data confirm previous cell-based studies
(21) indicating that NF-κB potentiates K-Ras transformation in the lung independently of the
status of p53.
Furthermore, loss of p65/RelA in K-RasG12D/p53Δ mice resulted in lower grade tumors. As
outlined in Fig. 4B, K-RasG12D/p53Δ/p65Δ mice have a significantly higher percentage of grade
1 tumors than K-RasG12D/p53Δ/p65WT mice. Conversely, RasG12D/p53Δ/p65Δ mice have a
significantly lower percentage of Grade 4 and 5 tumors. This indicates that p65/RelA regulates
not only survival of lung cells upon K-Ras activation, but also that it regulates other cell
properties that contribute to progression of the malignant phenotype
NF-κB is activated in human K-Ras-transformed lung epithelial cells and activation requires
IKKβ activity
The above experiments demonstrate that K-Ras activates NF-κB in the mouse lung, but it is
important to confirm that the same relationship exists in human lung cells. Therefore, NF-κB
activity was measured in low-passage primary immortalized human small airway cells
(SALEB) and their K-Ras-transformed counterparts (SAKRAS) (30). As can be seen in Fig.
5A, SAKRAS display p65-associated DNA binding activity (NF-κB band in untreated lane),
whereas SALEB cells do not. SAKRAS cells also display increased sensitivity to cytokine-
induced NF-κB activation (compare TNFα lanes). In addition, when compared to SALEB cells,
SAKRAS display highly elevated expression of NF-κB target genes IL-8 and MMP-9 and
slightly elevated expression of Bcl-XL (Fig. 5B). Finally, similar to the murine lung tumors,
SAKRAS cells also have increased levels of phosphorylated IκBα (Fig. 5C). Importantly,
SAKRAS cells exhibit elevated phosphorylated IKK (Fig. 5C, and see below).
In addition, we investigated NF-κB activity in H358 cells, a lung adenocarcinoma-derived cell
line known to harbor a K-Ras oncogenic mutation (34). As shown in Fig. 6A (left panel), H358
cells exhibit constitutive NF-κB DNA binding activity that is suppressed upon siRNA-
mediated knockdown of K-Ras expression, demonstrating that the majority of NF-κB DNA
binding activity in these cells is derived downstream of K-Ras expression.
Because of the increased level of phospho-IκBα detected in mouse tumors (Fig. 1D) and the
increased levels of phosphorylated forms of both IκBα and IKKα/β in SAKRAS cells (Fig.
5C), we asked if NF-κB activation induced by K-Ras is mediated by IKK. First, we tested a
potent IKKβ inhibitor (cmpdA (31)) in SAKRAS cells. IKKβ inhibition, but not control
treatment, blocked constitutive NF-κB DNA binding activity (Fig. 5A). Additionally IKKβ
inhibition blocked K-Ras-induced target gene expression (Fig. 5B).
We then explored siRNA knockdown to IKKβ in H358 cells. Knockdown of IKKβ strongly
suppressed NF-κB DNA binding activity in H358 cells, similar to siRNA-mediated knockdown
of K-Ras (Fig. 6A). Additionally, H358 cells were either transfected with a kinase-inactive
version of IKKβ (IKKβ-KM) or treated with CmpdA, and NF-κB-dependent reporter activity
was measured using luciferase. Results from these experiments demonstrate that both kinase-
inactive IKKβ and CmpdA block NF-κB activity (Figs. 6B and C), indicating the involvement
of IKK in the K-Ras-induced pathway. Finally we investigated whether pharmacological
inhibition of IKKβ would also affect NF-κB activity in mouse cells. For this purpose we used
the KE67 cell line derived from lung tumors of our K-RasG12D/NF-κB EGFP reporter mice.
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As can be seen on Fig. 6D, treatment of KE67 cells with CpA reduced the number of EGFP-
positive lung tumor cells by almost 50%.
Taken together, these results indicate that IKKβ plays an important role in mediating NF-κB
activation by K-Ras, supporting its inhibition in K-Ras-induced lung cancer as a potential new
therapeutic approach.
DISCUSSION
Point mutations in K-Ras occur frequently in lung cancer and drive the oncogenic phenotype.
Since there are no effective therapies for K-Ras-positive lung cancer (or for lung cancer
broadly), new approaches for therapy must be identified. In this regard, current interest is
focused on downstream oncogenic effectors of the activated Ras forms (35–38). Previously
we had shown that the transcription factor NF-κB is critical for oncogenic transformation
downstream of H-Ras (18,21). Furthermore, trying to dissect the role of the NF-κB subunits
in Ras-transformation, our group also showed that the p65/RelA subunit contributes to efficient
H-Ras-induced transformation (39). Additional studies have shown that p65/RelA is activated
in tumor biopsies from K-Ras-induced lung cancer patients (20), in K-Ras positive prostate
epithelial cells (22) and in both pancreatic cancer cells and melanoma cells in a Ras-dependent
manner (40,41). Here we have analyzed a role for the p65/RelA subunit of NF-κB downstream
of oncogenic K-Ras for the development of lung tumors in situ.
Using LSL-K-RasG12D mice (24), we show that K-Ras activates NF-κB in lung tumors in
situ (Fig. 1). Recently, Meylan et al (42) reported that NF-κB activation in the LSL-K-
RasG12D lung tumor model depends on deletion of p53. Our studies clearly show that NF-κB
activation occurs when p53 is wildtype. Meylan et al (42) analyzed nuclear accumulation of
p65/RelA as a marker of NF-κB activation, while our studies utilized NF-κB-dependent EGFP
reporter and IκBα phosphorylation from in situ tumors (Fig. 1). Thus, the use of distinct assays
with different sensitivity likely explain the differences in findings from the two papers,
specially as loss of p53has been shown to further enhance NF-κB activation (43). More
importantly, Meylan et al (42) reported that expression of a degradation-resistant form of
IκBα (IκBα-SR) suppressed tumor formation in the K-Ras lung tumor model with deleted p53.
Consistent with their findings, our results show that p65/RelA is needed for efficient lung tumor
formation by K-RasG12D regardless of p53 status (Figs. 2 and 4).
Furthermore, consistent with the previous cell-based studies (21), cre-generated deletion of
p65/RelA in parallel with K-RasG12D activation led, not only to reduced transformation (Fig.
2), but also to an apoptotic response in surviving tumors (Fig. 3). This result suggests that the
reduction in lung tumor number in the p65/RelA null setting is caused through an apoptotic
response, with the surviving tumors presumably undergoing less (but measurable) apoptosis,
which suggests that a likely mechanism for p65/RelA’s role in potentiating transformation is
to promote cell survival. In this regard, we have not detected significant upregulation of
traditional anti-apoptotic genes by oncogenic H-Ras (39) or by K-Ras (unpublished and Fig.
5B). Future experiments will address mechanisms of survival controlled by p65/RelA
downstream of oncogenic Ras expression.
The loss of p65/RelA significantly reduces, but does not eliminate, tumorigenesis downstream
of oncogenic K-Ras expression (Figs. 2 and 4). We have previously shown that Ras-induced
transformation is also impaired in c-Rel null MEFs, and that impairment is highest in c-Rel/
p65 double null MEFs (39), which suggests that both NF-κB subunits play an important role
in Ras-mediated transformation. Consistent with our previous work, Barbie at al (44) have
shown that c-Rel expression is important for survival of K-Ras-transformed cells. Meylan et
al (2009) have detected both c-Rel and p65/RelA activation in the LSL-K-RasG12D/p53Δ mouse
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model. These studies, together with the results described in this manuscript are consistent with
a model where both NF-κB subunits would be activated by K-Ras to promote oncogenesis.
Even though regulation of cell survival by p65/RelA certainly plays a role promoting K-Ras
transformation, the reduced grade of p65/RelA null K-Ras/p53Δ lung tumors (Fig. 4B) suggests
that p65/RelA regulates additional aspects of the malignant phenotype. Interestingly, in the
panel of genes analyzed in human primary cells, the two most strongly K-Ras-induced genes
were found to be IL-8 and MMP-9 (Fig. 5B), both of which have been shown to be important
in tumor progression. IL-8 was shown to promote Ras-induced angiogenesis (45), and MMP-9
has been shown to induce tumor invasion (46). Thus, in addition to controlling survival, NF-
κB activation by oncogenic K-Ras likely involves additional oncogenic mechanisms, including
enhanced invasion.
For therapy design purposes, it is important to identify mediators of K-Ras-induced NF-κB
activation that can be pharmacologically targeted. Here we identify IKKβ as an important
mediator of NF-κB activity in lung primary cells and lung cancer cell lines (Figs. 5 and 6).
This is consistent with additional evidence that IKKβ is activated by oncogenic Ras (22,23,
41,47), as well as evidence that IKKβ promotes oncogenesis. Loss of IKKβ prevents
tumorigenesis in a mouse model of colitis-associated cancer (48). Pharmacological inhibiton
of IKKβ inhibits multiple myeloma cell growth in vitro and as xenograft tumors (49).
Knockdown of IKKβ expression inhibits growth of H-Ras-driven melanomas (41). Finally,
IKKβ not only activates mTOR in certain breast cancer cells, thereby promoting tumor
angiogenesis, but its expression correlates with poor clinical outcome (50). Interestingly, the
IKK-related kinase TBK1 has been recently implicated in K-Ras-induced transformation and
NF-κB activation (44,51). It remains to be determined whether IKKβ and TBK1 contribute to
K-Ras-induced NF-κB activation independently, or whether there is a functional connection
between these two pathways. In this regard, TBK1 and IKKβ may contribute to different
oncogenic phenotypes, with TBK1 serving as a stronger regulator of cancer cell survival.
In summary, our studies show that K-Ras triggers NF-κB activation in a mouse model of lung
cancer in situ. NF-κB is an important K-Ras target in mediating the oncogenic process, because
loss of the NF-κB subunit p65/RelA significantly impairs lung tumor formation in the presence
or absence of p53. In addition, inhibiton of IKKβ expression or function blocks NF-κB
activation in K-Ras-transformed lung cells, suggesting pharmacological targeting of IKKβ or
other upstream regulators that control NF-κB as a potential therapeutic approach for K-Ras-
induced lung cancer therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Oncogenic K-Ras activates NF-κB in lung tumors in situ
WT and K-RasG12D/NF-κB mice were analyzed at 19 weeks post-infection. A) In vivo live
EGFP fluorescence emission. Color scale indicates the range of fluorescence intensity. B) Laser
scanning microscopy of dissected lungs to measure EGFP fluorescence emission. C) Lung
tissue sections of WT and K-RasG12D/NF-κB mice were analyzed by GFP
immunohistochemistry (positive cells stain in brown). Slides were counterstained with
hematoxylin (blue). D) Lung protein lysates from K-RasG12D or K-RasWT mice were submitted
to western blotting with the indicated antibodies. Arrows indicate the specific immunodetected
bands; additional bands in blots are non-specific.
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Figure 2. Loss of p65/RelA reduces formation and spread of K-Ras-induced lung tumors
K-RasG12D/p65WT and K-RasG12D/p65Δ mice were analyzed at 13 weeks post-infection. A)
Number of K-Ras-induced neoplastic lesions was determined by counting lesions in
Hematoxylin/Eosin stained lung sections as described (see methods). B) PCR to detect cre-
mediated recombination of p65/RelA. Bands corresponding to the WT and excised alleles are
indicated. C) Immunohistochemistry for p65/RelA (positive cells are brown). Neoplastic lesion
and adjacent epithelium are indicated. D) Analysis of lung tumor spread was performed on
Hematoxylin/Eosin stained lung sections as described (see methods).
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Figure 3. K-RasG12D/p65Δ lung tumors have higher numbers of apoptotic cells
Apoptotic cells were detected by TUNEL staining of lung tissue sections (positive cells are
brown).
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Figure 4. Loss of p65/RelA reduces formation and grade of K-Ras-induced lung tumors in the
absence of p53
K-RasG12D/p53Δ/p65WT and K-RasG12D/p53Δ/p65Δ mice were analyzed at 19 weeks post-
infection. A) Number of K-Ras-induced neoplastic lesions was determined by counting lesions
in Hematoxylin/Eosin stained lung sections as described (see methods). B) Analysis of lung
tumor grade was performed on Hematoxylin/Eosin stained lung sections as described (see
methods).
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Figure 5. K-Ras-induced NF-κB activation in lung primary cells requires IKKβ activity
A) Nuclear extracts of lung primary SALEB and SAKRAS cells were analyzed by EMSA with
a probe containing a canonical NF-κB DNA binding site. Cells were eiter left untreated (UT)
or treated for 1h with 20ng/ml TNFα (TNFα), 1uM CmpdA (CmpdA) or 0.02% DMSO
(DMSO). B) Expression of NF-κB target genes IL-8, Bcl-XL and MMP-9 was analyzed by
real-time quantitative PCR in SALEB and SAKRAS cells treated with 0.02% DMSO (DMSO)
or 1uM CmpdA (CmpdA) for 24h. C) Western blotting of total protein lysates from SALEB
(SL) or SAKRAS (SK) cells probed with different antibodies as indicated.
Basseres et al. Page 17













Figure 6. K-Ras-induced NF-κB activation in lung cancer cells requires IKKβ expression and
activity
A) H358 cells were transiently transfected with siRNA targeted against K-Ras (siK-Ras),
IKKβ (siIKKβ), and nontargeting control (siCtrl) and analyzed at 96h post-transfection for NF-
κB DNA binding activity by EMSA (left panel) and efficiency of knockdown by Western
Blotting (WB, right panel). NF-κB DNA binding complexes as well as antibodies used are
indicated. B and C) Dual luciferase reporter assays were performed using an NF-κB-
responsive firefly luciferase reporter (3x-κB-Luc, unfilled bars) or an NF-κB-unresponsive
reporter (3X-MUTκB-Luc, black-filled bars). For panel B, H358 cells were either transfected
with an empty pcDNA3 vector (VC) or with pcDNA3-IKKβ-KM. For panel C, H358 cells
were either treated with 0.02% DMSO or treated 1uM CmpdA for 16h. D) DMSO or CmpdA-
treated KE67 cells were analyzed by flow cytometry. Forward and side scatter (FS and SS)
were used to gate on live cells. The single color histogram represents the number of events
recorded in function of the level of GFP fluorescence emission using a logaritmic scale. A
threshold for GFP-positive cells was arbitrarily set (linear gate) and the percentage of GFP
positive cells is indicated.
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